UA108466C2 - Antibody antagonises c-Met - Google Patents

Antibody antagonises c-Met

Info

Publication number
UA108466C2
UA108466C2 UAA201108288A UAA201108288A UA108466C2 UA 108466 C2 UA108466 C2 UA 108466C2 UA A201108288 A UAA201108288 A UA A201108288A UA A201108288 A UAA201108288 A UA A201108288A UA 108466 C2 UA108466 C2 UA 108466C2
Authority
UA
Ukraine
Prior art keywords
cdr
antibody
met
seq
amino acid
Prior art date
Application number
UAA201108288A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Priority claimed from PCT/EP2009/066201 external-priority patent/WO2010069765A1/en
Publication of UA108466C2 publication Critical patent/UA108466C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід стосується химерного або гуманізованого моноклонального антитіла, здатного інгібувати димеризацію с-Мet, де дане антитіло включає важкий ланцюг, що включає CDR-H1, CDR-H2 і CDR-H3 з відповідними амінокислотними послідовностями SEQ ID NO: 1, 2 і 3; і легкий ланцюг, що включає CDR-L1, CDR-L2 і CDR-L3 з відповідними амінокислотними послідовностями SEQ ID NO: 5, 6 і 7, де дане антитіло додатково характеризується тим, що воно також включає шарнірну область, яка включає амінокислотну послідовність вибрану з групи, що складається з SEQ ID NO: 22-24, 26, 28, 59-63 та 65-71. Винахід стосується також композиції, яка включає таке антитіло, та її застосування як ліків для лікування раку.The invention relates to a chimeric or humanized monoclonal antibody capable of inhibiting dimerization of c-Met, where the antibody includes a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with the corresponding amino acid sequences of SEQ ID NO: 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with the corresponding amino acid sequences of SEQ ID NO: 5, 6 and 7, where the antibody is further characterized in that it also includes a hinge region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 22-24, 26, 28, 59-63 and 65-71. The invention also relates to a composition comprising such an antibody and its use as a medicament for the treatment of cancer.

UAA201108288A 2008-12-02 2009-02-12 Antibody antagonises c-Met UA108466C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
PCT/EP2009/066201 WO2010069765A1 (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Publications (1)

Publication Number Publication Date
UA108466C2 true UA108466C2 (en) 2015-05-12

Family

ID=40875044

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108288A UA108466C2 (en) 2008-12-02 2009-02-12 Antibody antagonises c-Met

Country Status (2)

Country Link
UA (1) UA108466C2 (en)
WO (1) WO2010064089A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
CN103003307B (en) 2010-03-10 2017-08-11 根马布股份公司 Anti- c MEt monoclonal antibody
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
CA2809677A1 (en) 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
KR20130037153A (en) * 2011-10-05 2013-04-15 삼성전자주식회사 Anti c-met antibody and uses thereof
KR101865223B1 (en) 2011-10-05 2018-06-08 삼성전자주식회사 Anti c-Met humanized antibody and uses thereof
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
KR102049990B1 (en) * 2013-03-28 2019-12-03 삼성전자주식회사 Fusion protein comprising anti-c-Met antibody and VEGF binding fragment
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
CN107613974B (en) * 2015-03-16 2021-01-15 塞尔德克斯医疗公司 anti-MET antibodies and methods of use thereof
WO2017201204A1 (en) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2024030341A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2004298483A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
MX2007001470A (en) * 2004-08-05 2007-03-26 Genentech Inc Humanized anti-cmet antagonists.
BRPI0709917A2 (en) * 2006-03-30 2011-07-05 Novartis Ag compositions and methods of use for c-met antibodies

Also Published As

Publication number Publication date
WO2010064089A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
UA108466C2 (en) Antibody antagonises c-Met
NZ596837A (en) Anti-vegf antibodies and their uses
PE20120343A1 (en) ANTI-CMET ANTIBODY INCLUDING A HINGED REGION
NZ585559A (en) Humanized antibodies against tl1a
RU2012147286A (en) HUMANIZED ANTIBODIES TO FACTOR D AND THEIR APPLICATIONS
RS52919B (en) Sclerostin binding agents
MX2018014714A (en) Compositions for inhibiting masp-2 dependent complement acitivation.
RU2012154339A (en) NEW ANTI-BODY AGAINST c-Met
NZ613716A (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
NZ603045A (en) Tnf-alpha binding proteins
TW200720289A (en) Antibodies against CCR5 and uses thereof
RS54452B1 (en) Compositions and methods for diagnosing and treating cancer
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
CL2013003373A1 (en) B binding protein to the b-cell maturation antigen (bcma); pharmaceutical composition comprising the protein; use to prepare a useful medication to treat multiple myeloma or (mm) chronic lymphocytic leukemia (cll).
AR080501A1 (en) ANTIBODIES ANTI FACTOR ANTIGENIC DETERMINANT OF PROGRAMMED DEATH 1 (ANTI-PD1)
NZ595687A (en) Anti-tnf-alpha antibodies and their uses
JP2016512551A5 (en)
NZ596136A (en) Anti-cd100 antibodies and methods for using the same
RU2014143784A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF GALLERY BLADDER CANCER
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2014143785A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF LIVER CANCER
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
AR080243A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
RS53405B (en) Humanized anti cxcr4 antibodies for the treatment of cancer
NZ705653A (en) Novel antibody for the diagnosis and/or prognosis of cancer